Patrick Weston
Cardiovascular Disease · Bradenton, FLNPI 1306813423
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Merck at 57.3% of the total. 2024 is the largest year on record at $3,542, more than ten times the $290 reported in 2019.
Across 29 payments — averaging $135.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Echosens North America, Inc.$1K
- Biosense Webster, Inc.$99
- Gilead$89
- United Therapeutics Corporation$77
- Amarin Pharma, Inc.$45
- plus $169 from 8 others
Across 724 payments — averaging $1769.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$304K
- Boehringer Ingelheim International GmbH$194K
- Pfizer$143K
- AstraZeneca$140K
- Eli Lilly$101K
- Alnylam Pharmaceuticals Inc.$91K
- plus $308K from 12 others
What the payments were for
- Consulting fees$1,20031%
- Travel & lodging$2,12254%
- Food & beverage$57215%
- Education$381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 11 | $2,253 |
| Echosens North America, Inc. | 2 | $1,200 |
| Biosense Webster, Inc. | 1 | $99 |
| Gilead | 1 | $89 |
| United Therapeutics Corporation | 1 | $77 |
| Amarin Pharma, Inc. | 2 | $45 |
| Boehringer Ingelheim | 2 | $38 |
| AstraZeneca | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 2 | $26 |
| Medtronic | 1 | $20 |
| Pfizer | 1 | $15 |
| Amgen | 1 | $15 |
| Boston Scientific | 1 | $13 |
| Penumbra, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FibroScan$1,200
How this compares
$3,932 in reported general payments places this provider in the 55th percentile of 1,740 cardiovascular disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pindolol | 11 | $811 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Bradenton
- Eugene ParentBradenton$302K
- Iftekhar BaigBradenton$249K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.